Fujihara K
Department of Neurology, Tohoku University School of Medicine.
Rinsho Shinkeigaku. 1999 Jan;39(1):21-3.
HTLV-I proviral DNA load is significantly increased in HTLV-I associated myelopathy (HAM) compared with asymptomatic HTLV-I seropositive carriers (SPC), and this spread of HTLV-I infection seems to be critically important in the pathogenesis of HAM. Thus, in this report, cellular immune surveillance against HTLV-I was reviewed. (1) MHC class I-restricted cytotoxic T lymphocytes (CTL) activities are detected in peripheral blood mononuclear cells (PBMC) of HAM. CTL release various proinflammatory and cytotoxic cytokines, chemokines, and proteases. Since CTL are also found in the spinal lesions of HAM, CTL may contribute to the tissue damage. In spontaneous proliferation of PBMC in HAM, CD 4/CD 8 is decreased due to the proliferation of CD 8 + CTL. CD 4/CD 8 is inversely correlated with the clinical severity of HAM. Collectively, CTL may be involved in the pathogenesis of HAM. (2) Activity and subsets of natural killer (NK) cells are lower in HTLV-I-seropositive individuals. Moreover, NK have only a weak cytotoxicity against HTLV-I infected cells. (3) Antibody-dependent cell-mediated cytotoxicity (ADCC) are impaired in HAM compared with SPC due to the suppressed effector cell activity. Since ADCC effectively lyse HTLV-I infected cells in vitro, the impaired ADCC may in part allow the spread of HTLV-I infection in HAM, and potentiation of ADCC may have an anti-HTLV-I therapeutic effect.
与无症状的人类嗜T淋巴细胞病毒I型(HTLV-I)血清反应阳性携带者(SPC)相比,HTLV-I相关脊髓病(HAM)患者的HTLV-I前病毒DNA载量显著增加,HTLV-I感染的这种扩散似乎在HAM的发病机制中至关重要。因此,在本报告中,对针对HTLV-I的细胞免疫监测进行了综述。(1)在HAM患者的外周血单个核细胞(PBMC)中检测到主要组织相容性复合体I类(MHC-I)限制性细胞毒性T淋巴细胞(CTL)活性。CTL释放多种促炎和细胞毒性细胞因子、趋化因子及蛋白酶。由于在HAM患者的脊髓病变中也发现了CTL,CTL可能导致组织损伤。在HAM患者PBMC的自发增殖中,由于CD8+CTL的增殖,CD4/CD8降低。CD4/CD8与HAM的临床严重程度呈负相关。总体而言,CTL可能参与了HAM的发病机制。(2)HTLV-I血清反应阳性个体的自然杀伤(NK)细胞活性和亚群较低。此外,NK细胞对HTLV-I感染细胞的细胞毒性较弱。(3)与SPC相比,HAM患者的抗体依赖性细胞介导的细胞毒性(ADCC)因效应细胞活性受抑制而受损。由于ADCC在体外可有效裂解HTLV-I感染的细胞,ADCC受损可能在一定程度上导致了HTLV-I在HAM中的感染扩散,增强ADCC可能具有抗HTLV-I的治疗作用。